Patent Application
20210196787
The present invention relates to an agent for enhancing phagocytosis ability of neutrophils, and more particularly, to an agent for enhancing phagocytosis ability of neutrophils including a histidine-rich glycoprotein as an active ingredient.
The present application claims priority from Japanese Patent Application No. 2018-123626, which is incorporated herein by reference.
Neutrophils have migration, phagocytosis, and microbicidal functions. Phagocytosis ability (phagocytosis) is the first barrier of living bodies against microbe invasion, and is regarded as important as a fundamental function of immune systems. The main role of neutrophils is a biological defense function: phagocytosing foreign matter, typically pathogenic microbes invading living bodies; and killing the microbes with reactive oxygen species generated therefrom. Neutrophils have non-specific immune ability to eliminate substances that invade living bodies. When immunoglobulins, complements, or the like bind to foreign matter to cause opsonization (Op), neutrophils recognize and phagocytose the foreign matter. However, no therapeutic agent for enhancing bacterium phagocytosis activity has been known. There has been demanded a method for ameliorating a bacterium clearance disorder due to lowered bacterium phagocytosis ability of neutrophils.
Histidine-rich glycoprotein (HRG) is a plasma protein having a molecular weight of about 80 kDa, which was identified by Heimburger et al. (1972). HRG is a histidine-rich protein formed of a total of 507 amino acids including 66 histidines, is mainly synthesized in the liver, and is present in human plasma at a concentration of from about 100 μg/mL to about 150 μg/mL, which is regarded as extremely high. It is known that HRG is involved in regulation of coagulation and fibrinolytic systems and regulation of angiogenesis (Non Patent Literature 1). Further, there are disclosures of: methods for the inhibition of angiogenesis by administering an HRG polypeptide; and pharmaceutical compositions and articles of manufacture including HRG polypeptides, antibodies and receptors that bind to an HRG polypeptide, HRG-depleted plasma and polynucleotides, vectors and host cells that encode HRG polypeptides (Patent Literature 1). In addition, there is a disclosure relating to the field of angiogenesis, and more particularly to the use of a substantially pure consecutive polypeptide having anti-angiogenic activity, including subfragments derived from a central region of HRG (Patent Literature 2). Further, there is also a disclosure of a depressant agent for neutrophil-vascular endothelial cell adhesion, containing HRG as an active ingredient (Patent Literature 3). In Patent Literature 3, there is a disclosure of a regulatory action on neutrophil activation including HRG as an active ingredient. However, bacterium phagocytosis activity of neutrophils and the like has not been reported.
There is a disclosure that a protein of interest was generated using a gene expression cassette of a special structure (Patent Literature 4). In Patent Literature 4, there is a description that cells capable of stably and highly producing the protein of interest are obtained through use of the gene expression cassette, and as examples of the generated protein, HRG, an HRG-Fc fusion protein, and the like are described in Examples. Fusion products of an Fc domain of IgG with specific substances, such as proteins classified into receptors, cytokines, peptides, and enzymes, are known, which have artificially been designed expecting a prolonged half-life in blood. However, the action of an HRG-Fc fusion protein has not been reported yet.
An object of the present invention is to provide an agent for enhancing phagocytosis ability of neutrophils. Another object of the present invention is to provide an agent for enhancing phagocytosis ability of neutrophils as a therapeutic agent or therapeutic adjunct for various bacterial infectious diseases, viral infectious diseases, fungal infectious diseases, parasitic infectious diseases, and mixed infectious diseases thereof.
The present invention is directed to an agent for enhancing phagocytosis ability of neutrophils, including HRG as an active ingredient. To solve the above-mentioned objects, the inventors of the present invention have focused attention on HRG having a regulatory function of neutrophil activities, and as the result of extensive investigations, have newly found that HRG exhibits an enhancing effect of phagocytosis ability against pathogens or foreign matter caused by bacteria, viruses, fungi, parasites, and the like among the neutrophil activities, thus completing the present invention.
That is, the present invention includes the following.
1. An agent for enhancing phagocytosis ability of neutrophils, including a histidine-rich glycoprotein as an active ingredient.
2. The agent for enhancing phagocytosis ability of neutrophils according to the above-mentioned item 1, wherein the histidine-rich glycoprotein, which is the active ingredient, is present in the form of an Fc-fusion protein including the histidine-rich glycoprotein fused with an Fc region of an antibody.
3. The agent for enhancing phagocytosis ability of neutrophils according to the above-mentioned item 2, wherein the Fc region of an antibody is an Fc region derived from IgG2.
4. The agent for enhancing phagocytosis ability of neutrophils according to any one of the above-mentioned items 1 to 3, wherein the agent serves as a therapeutic agent for an infectious disease or a therapeutic adjunct for an infectious disease.
5. The agent for enhancing phagocytosis ability of neutrophils according to the above-mentioned item 4, wherein the infectious disease is an infectious disease caused by a pathogen derived from one or a plurality of species selected from bacteria, viruses, fungi, and parasites.
6. The agent for enhancing phagocytosis ability of neutrophils according to the above-mentioned item 4 or 5, wherein the infectious disease is anyone of infectious diseases selected from a respiratory infectious disease, a urinary tract infectious disease, a biliary tract infectious disease, a gastrointestinal infectious disease, and a central nervous system infectious disease.
A. A method of enhancing phagocytosis ability of neutrophils using HRG as an active ingredient of an agent for enhancing phagocytosis ability of neutrophils.
B. A therapeutic method for an infectious disease or an adjunctive therapeutic method for an infectious disease using HRG as an active ingredient of an agent for enhancing phagocytosis ability of neutrophils.
C. The method of enhancing phagocytosis ability of neutrophils according to the above-mentioned item A, or the therapeutic method for an infectious disease or the adjunctive therapeutic method for an infectious disease according to the above-mentioned item B, wherein the HRG, which is the active ingredient, is in the form of an Fc-fusion protein including the HRG fused with an Fc region of an antibody.
D. The method of enhancing phagocytosis ability of neutrophils, or the therapeutic method for an infectious disease or the adjunctive therapeutic method for an infectious disease according to the above-mentioned item C, wherein the Fc region of an antibody is an Fc region derived from IgG2.
E. The therapeutic method for an infectious disease or the adjunctive therapeutic method for an infectious disease according to the above-mentioned item D, wherein the infectious disease is an infectious disease caused by a pathogen derived from one or a plurality of species selected from bacteria, viruses, fungi, and parasites.
F. The therapeutic method for an infectious disease or the adjunctive therapeutic method for an infectious disease according to the above-mentioned item D or E, wherein the infectious disease is any one of infectious diseases selected from a respiratory infectious disease, a urinary tract infectious disease, a biliary tract infectious disease, a gastrointestinal infectious disease, and a central nervous system infectious disease.
The agent for enhancing phagocytosis ability of neutrophils including HRG as an active ingredient according to the present invention (hereinafter sometimes abbreviated as “agent for enhancing phagocytosis ability of neutrophils” of the present invention) has an action of effectively enhancing phagocytosis ability of neutrophils against foreign matter, such as a bacterium, upon having been caused to act on neutrophils in a normal condition.
The present invention relates to an agent for enhancing phagocytosis ability of neutrophils, including HRG as an active ingredient.
The main role of neutrophils is a biological defense function: phagocytosing foreign matter, typically pathogenic microbes invading living bodies; and killing the microbes with reactive oxygen species generated therefrom. Neutrophils have non-specific immune ability to eliminate substances that invade living bodies. When immunoglobulins, complements, or the like bind to foreign matter to cause opsonization (Op), neutrophils recognize and phagocytose the foreign matter. However, no therapeutic agent for enhancing a bacterium phagocytosis activity of neutrophils has been known. There has been demanded a method for ameliorating a bacterium clearance disorder due to lowered bacterium phagocytosis ability of neutrophils.
The HRG, included as the active ingredient in the “agent for enhancing phagocytosis ability of neutrophils” of the present invention, can be prepared by a method for isolation or purification from a biological component, a method for preparation using a recombination technology, or synthesis; and the purity thereof is not particularly limited to the maximum purity. The HRG can be subjected to, for example, purification and/or isolation from a biological component such as: blood, for example, plasma or serum; spinal fluid; or lymphatic fluid. The biological component is suitably a blood component, such as plasma or serum. A method known per se or any method to be developed in the future may be applied as the method for the isolation/purification from a biological component. For example, the HRG may be prepared bypassing plasma through an affinity column prepared using a nickel-nitrilotriacetic acid (Ni-NTA) agarose resin.
A method known per se or any method to be developed in the future may be applied as the method for the preparation of HRG using a recombination technology. For example, the preparation can be performed by cloning the full-length cDNA encoding HRG or a cDNA encoding a part having the activity of HRG into an expression vector. For example, a protein biosynthesized from the whole or a part of the nucleotide defined by GenBank Accession No. NM000412 can be used. For example, the preparation can be performed by cloning the full-length cDNA encoding the amino acid sequence of mature HRG (SEQ ID NO: 1) or a cDNA encoding a part thereof into an expression vector. The HRG included as the active ingredient in the “agent for enhancing phagocytosis ability of neutrophils” of the present invention can optionally be an HRG protein itself, or a part of a protein or peptide having the activity of HRG. The HRG can be with or without a carbohydrate chain. The mature HRG, following truncation of its signal peptide by a proteinase, includes four principal regions: (1) cystatin-like region 1, (2) cystatin-like region 2, (3) a His/Pro region, and (4) a C-terminal region. The His/Pro region is extremely rich in proline residues and histidine residues, and can be defined by the amino acid sequence shown as amino acids 330 to 389 of the amino acid sequence set forth in SEQ ID NO: 1.
Specifically, a method described in Patent Literature 4 can be applied as a method of generating HRG through use of a recombination technology. For example, a full-length cDNA encoding HRG, or cDNA encoding a part having the activity of HRG, such as a full-length cDNA encoding the amino acid sequence (SEQ ID NO: 1) of the mature HRG, or a cDNA encoding a part thereof, is cloned into an expression vector to prepare a desired HRG expression vector. The HRG protein can be prepared by, for example, using an HRG-carrying construct illustrated in
To prepare an HRG-Fc fusion protein, it is suitable to bind a cDNA encoding Fc to a portion encoding the C′-terminal region of HRG. An HRG protein included in the HRG-Fc fusion protein of the present invention can be the whole mature HRG, or those with or without a carbohydrate chain, as well as a part of a protein or peptide having the activity of HRG out of the mature HRG.
The Fc included in the HRG-Fc fusion protein can be any polypeptide defining an Fc region of an antibody. The antibody includes polypeptides called a heavy chain (H chain) and a light chain (L chain). The H chain includes a variable region (VH) and a constant region (CH) from its N-terminus, and the L chain includes a variable region (VL) and a constant region (CL) from its N-terminus. The CH includes domains CH1, hinge, CH2, and CH3 from its N-terminus. The region including both CH2 and CH3 is called an Fc region. Examples of classes of the antibody include IgG, IgA, IgE, and IgM. Examples of subclasses of the IgG include IgG1, IgG2, IgG3, and IgG4. The Fc region used for the HRG-Fc fusion protein of the present invention can be derived from any of the subclasses IgG1, IgG2, IgG3, and IgG4, particularly suitably IgG2. The use of the Fc region of IgG2 can lead to be low complement activity, ameliorating aside effect inflammatory reaction. The amino acid sequence of the Fc region of human IgG2 is set forth in SEQ ID NO: 2.
Proteins, peptides, and the like, which are generally believed to be less stable and less efficient in living bodies, may be fused with an Fc region, achieving improved stability and efficacy in a formulation. The use of the Fc region of human IgG2 allows a pharmaceutical formulation having a lower complement activity and an ameliorated side effect inflammatory reaction.
The “agent for enhancing phagocytosis ability of neutrophils” of the present invention can enhance the bacterium phagocytosis activity of neutrophils and the like. The above-mentioned “agent for enhancing phagocytosis ability of neutrophils” of the present invention may include HRG as an active ingredient, and may include, for example, HRG per se and/or an HRG-Fc fusion protein as well as a pharmacologically acceptable carrier. Examples of the pharmacologically acceptable carrier may include excipients, disintegrants or disintegration aids, binders, lubricating agents, coating agents, dyes, diluents, bases, solubilizing agents or dissolution aids, tonicity agents, pH adjusters, stabilizers, propellants, and pressure-sensitive adhesives.
The “agent for enhancing phagocytosis ability of neutrophils” of the present invention can enhance phagocytosis ability of neutrophils against a pathogen or foreign matter derived from bacteria, viruses, fungi, or parasites. Thus, the “agent for enhancing phagocytosis ability of neutrophils” can be used for a therapeutic agent or therapeutic adjunct for a bacterial infectious disease, a viral infectious disease, a fungal infectious disease, a parasitic infectious disease, and mixed infectious diseases thereof. Examples of the infectious diseases applicable to the present invention may include the above-mentioned various infectious diseases, and may also include a respiratory infectious disease, a urinary tract infectious disease, a biliary tract infectious disease, a gastrointestinal infectious disease, and a central nervous system infectious disease. The present invention encompasses a therapeutic agent and therapeutic adjunct for such diseases.
The present invention also encompasses a method of enhancing phagocytosis ability of neutrophils using HRG as an active ingredient of an agent for enhancing phagocytosis ability of neutrophils. The present invention also encompasses a therapeutic method of an infectious disease or an adjunctive therapeutic method for an infectious disease using HRG as an active ingredient of an agent for enhancing phagocytosis ability of neutrophils.
The “agent for enhancing phagocytosis ability of neutrophils” of the present invention, when used as a therapeutic agent or therapeutic adjunct for the above-mentioned diseases, may topically or systemically be administered. Dosage forms for therapeutic and/or preventive agents may include enteral administration formulations and parenteral administration formulations. Examples of the parenteral administration formulations may include external preparations for transdermal administration, such as a lotion, an ointment, a tape, and a plaster, as well as those in the form suitable for topical administration by injection and the like, intravenous injection administration, and transluminal administration. The parenteral administration formulations may include a sterilized aqueous or nonaqueous solution, suspension, or emulsion. Examples of nonaqueous diluents are propylene glycol, polyethylene glycol, plant oils, such as olive oil, and organic ester compositions, such as ethyl oleate, which are suitable for injection. Aqueous carriers may include water, alcoholic/aqueous solutions, emulsions, suspensions, saline, and buffered media. Parenteral carriers may include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's, and fixed oils. Parenteral administration formulations in the form suitable for topical administration by injection or the like, intravenous injection administration, or intraluminal administration may include fillers for liquid, nutrients (including monosaccharides, oligosaccharides, polysaccharides, starches, or partial starch hydrolyzates) or electrolytes (e.g., those based on Ringer dextrose) as carriers. The “agent for enhancing phagocytosis ability of neutrophils” of the present invention may include a preservative and other additives, for example, an antimicrobial compound, an antioxidant, a chelating agent, and an inert gas.
When used as the therapeutic agent or therapeutic adjunct for the diseases described above, the “agent for enhancing phagocytosis ability of neutrophils” of the present invention can be administered in combination with any other pharmaceutical formulation. The other pharmaceutical formulation that can be used in combination should not be particularly limited, and may generally be any already commercially available therapeutic agent or preventive agent, or any therapeutic agent or preventive agent to be developed in the future. The other pharmaceutical formulation is suitably a pharmaceutical formulation having an action mechanism different from that of the “agent for enhancing phagocytosis ability of neutrophils” of the present invention. The “agent for enhancing phagocytosis ability of neutrophils” of the present invention can be used before, during or after use of a therapeutic agent and/or a preventive agent for an infectious disease known per se, including, for example, antibiotic agents, antimicrobial agents, and viral agents. The “agent for enhancing phagocytosis ability of neutrophils” of the present invention can be used in combination with any other pharmaceutical formulation to lower the dose of the other pharmaceutical formulation. When the other pharmaceutical formulation has a side effect, the combined use with the “agent for enhancing phagocytosis ability of neutrophils” of the present invention can reduce the dose/administration frequency of the other pharmaceutical formulation, achieving a practical advantage of reducing the side effect of the other pharmaceutical formulation. Each ingredient other than HRG as an active ingredient may be blended in any appropriate amounts that do not impair an intended purpose of the present invention.
The present invention is specifically described by way of the following Examples, experimental examples, and comparative examples, but it goes without saying that the present invention is not limited by these Examples and the like.
Human plasma was used as a starting raw material. Human plasma-derived HRG (hereinafter referred to as “hHRG”) was purified using Ni-NTA affinity chromatography and high performance liquid chromatography (anion exchange column (monodisperse hydrophilic polymer beads: Mono Q)). A purified hHRG sample was obtained in the molecular weight fraction of about 80 kDa. hHRG of this Example was generated by a method described in Example 1 of Patent Literature 3 (WO 2013/183494 A1). hHRG samples having various concentrations were generated through dilution with Hanks' solution (Hanks' Balanced Salt Solution: HBSS).
Recombinant human HRG (hereinafter referred to as “rHRG”) of this Example was generated by a method described in Example 3 of Patent Literature 4 (WO 2017/061354 A1). Into Chinese Hamster Ovary cells (CHO cells) cultured in 10% FCS-containing GIBCO™ Dulbecco's Modified Eagle Medium/Nutrient Mixture F-12 (DMEM/F12), an HRG expression vector, a transposase expression vector, and a drug-resistant gene expression vector (see
After the selection culture, rHRG-containing culture supernatant was recovered. To the culture supernatant, a QIAGEN™ Ni-NTA agarose gel prewashed with 30 mL of PBS(−) (a gel in which Ni-NTA was bound to Sepharose CL-6B support) was added, and the resulting culture was subjected to rotation incubation at 4° C. for 2 hours, allowing the rHRG to bind to the QIAGEN™ Ni-NTA agarose gel. After the QIAGEN™ Ni-NTA agarose gel was transferred to a column for purification, the column was sequentially washed with washing liquid 1 (30 mM imidazole-containing PBS(−) (pH 7.4)), washing liquid 2 (1 M NaCl+10 mM PBS (pH 7.4)), and washing liquid 3 (PBS (−) (pH 7.4)). The rHRG was eluted with 500 mM imidazole-containing PBS(−) (pH 7.4) at 4° C. rHRG samples having different concentrations were prepared by dilution with HBSS.
In this Example, a fusion protein of HRG+Fc of human IgG2 (hereinafter referred to as “HRG-Fc”) was generated. To a nucleic acid including the base sequence defined by the DNA encoding an HRG-coding region (GenBank Accession No. BC069574 (NCBI)), a nucleic acid including the base sequence encoding an Fc region of human IgG2 was bound to generate the HRG-Fc by a method described in Example 12 of Patent Literature 4 (WO 2017/061354 A1). HRG-Fc samples having different concentrations were prepared by dilution using HBSS. In the same manner as in Example 2, a DNA base sequence encoding an HRG-coding region (EcoR1-HRG-Xho1) is set forth in SEQ ID NO: 3 (
Phagocytosis ability of neutrophils against Escherichia coli (a gram-negative bacterium) or Staphylococcus aureus(a gram-positive bacterium) was measured with a pHrodo™ indicator. Phagosomes within neutrophils can be fluorescence-stained with a pHrodo™ staining reagent to measure their phagocytosis ability. Human neutrophils were separated from the whole blood using a hemocyte separation solution Polymorphprep™, and the cell solution was washed with PBS to perform suspension. The numbers of cells were adjusted, and the cells were stained with Hoechst33342 (nucleus staining: blue) and calcein-AM (cytoplasm: green) by incubation under CO2 at 37° C. for 15 min. Neutrophil solutions were resuspended in HBSS, and the numbers of cells were adjusted (2×106 cells/mL).
To the neutrophil liquids at the cell concentration, hHRG solutions were added, and the mixtures were dispensed to a 96-well plate, allowing incubation under CO2 at 37° C. for 30 min. Then, Escherichia coli (pHrodo™ Escherichia coli) or Staphylococcus aureus (pHrodo™ Staphylococcus aureus) was added to the 96-well plate, and incubated under CO2 at 37° C. In this Example, the final concentration of the cell liquids was 2×104 cells/well (2×105 cells/mL), the final concentrations of HRG were from 0.01 μM to 3.0 μM, and the final concentration of pHrodo™ Escherichia coli or pHrodo™ Staphylococcus aureus was 25 μg/well (250 μg/mL). The incubation of Escherichia coli was for 60 min, and that of Staphylococcus aureus was for 120 min.
Through use of InCell Analyzer (GE Healthcare), the amounts of red-colored pHrodo by neutrophils' uptake were analyzed by image analysis and quantification to observe the phagocytosis ability of neutrophils. The analysis results of phagocytosis ability of neutrophils against Escherichia coli and Staphylococcus aureus are shown in
The results reveal that HRG enhanced phagocytosis ability of neutrophils against Escherichia coli and Staphylococcus aureus. HRG is generally contained at about 1 μM in blood, and the phagocytosis ability with HRG in this Example reached a plateau at 0.3 μM, suggesting that bacterium phagocytosis ability of neutrophils in normal individuals' blood is constantly maintained and that such phagocytosis ability is lowered in conditions with lowered HRG, such as sepsis.
To the neutrophil liquids at the cell concentration (2×106 cells/mL), each solution of hHRG, rHRG, or HRG-Fc was added to observe the phagocytosis ability of neutrophils against Escherichia coli or Staphylococcus aureus by the same procedure as Experimental Example 1 (HRG final concentrations of from 0.1 μM to 3.0 μM). As an observation experiment, phagocytosis ability of neutrophils against Escherichia coli or Staphylococcus aureus was observed, when each of different anti-HRG antibodies or control antibodies was added. The amounts of red-colored pHrodo by neutrophils' uptake can be imaged and quantified to observe the phagocytosis ability of neutrophils.
The results reveal that rHRG enhances phagocytosis of neutrophils against Escherichia coli or Staphylococcus aureus to the same extent as hHRG, whereas HRG-Fc is weak in phagocytosis-enhancing ability.
Phagocytosis ability of neutrophils against Escherichia coli or Staphylococcus aureus was observed, when 1.0 μM of hHRG was added to neutrophil solutions at the cell concentration (2×106 cells/mL) by the same procedure as Example 1 or when each of 1.0 μM of IL-8, fMLP, and C5a or 10 μM of LPS was added as Comparative Example. The results of image analysis are shown in
Phagocytosis ability of neutrophils against Escherichia coli or Staphylococcus aureus was observed, when 1.0 μM of hHRG was added to neutrophil solutions at the cell concentration (2×106 cells/mL) by the same procedure as Example 1 or when each of 10 μM of different anti-HRG antibodies or control antibodies was added as an observation experiment. The results of analysis are shown in
HRG enhanced the phagocytosis ability of neutrophils against Escherichia coli or Staphylococcus aureus, whereas the addition of each anti-HRG antibody suppressed phagocytosis ability. In contrast, the addition of the control antibodies maintained the phagocytosis ability of neutrophils against Escherichia coli or Staphylococcus aureus. This reveals that HRG has an action of enhancing the phagocytosis ability of neutrophils.
In this Experimental Example, the effect of HRG on opsonization (Op) was observed using serum containing HRG or no HRG. Healthy human serum was used for opsonization (Op). In this Experimental Example, the “serum containing HRG” refers to untreated, healthy human serum. In this Experimental Example, the “serum containing no HRG” refers to human serum in which a Ni-NTA agarose gel is added to human serum to adsorb HRG in the serum, and then the Ni-NTA agarose gel is removed by centrifugation. A Western blotting revealed that no HRG was detected in the serum containing no HRG.
Zymosan (pHrodo™ Red Zymosan, manufactured by Thermo Fisher Scientific Inc.) was blended with serum containing HRG or no HRG at 4° C., and then the mixture was stirred well by ultrasonic homogenization. After the stirring, centrifugation was performed at 4° C. and 15,000 rpm for 15 min. The supernatant was discarded and the sediment was suspended in HBSS. This washing procedure was repeated twice, and then Zymosan was suspended in HBSS. The concentration of Zymosan at this time of point was 1.0 mg/mL.
To the neutrophil liquids, hHRG solutions were added, and the mixtures were dispensed to a 96-well plate, allowing incubation under CO2 at 37° C. for 30 min. Then, the Zymosan solution was added to the 96-well plate, which was then incubated under CO2 at 37° C. for 120 min. The final concentration of the cell liquids at this time was 2×104 cells/well (2×105 cells/mL), the final concentration of HRG was 1.0 μM, and the final concentration of Zymosan was 50 μg/well (500 μg/mL). Through use of InCell Analyzer (GE Healthcare), the amounts of red-colored pHrodo by neutrophils' uptake were analyzed by image analysis and quantification to observe the phagocytosis ability of neutrophils.
The result is shown in
Escherichia coli (pHrodo™ Escherichia coli) or Staphylococcus aureus (pHrodo™ Staphylococcus aureus) was pre-incubated with human serum albumin (HSA, 1.0 μM), hHRG (1.0 μM), or 5-fold-diluted human serum (1/5 Serum) at 37° C. for 15 min, and then Escherichia coli or Staphylococcus aureus was washed twice with HBSS. Then, an opsonin (Op)-enhancing effect of HRG against Escherichia coli or Staphylococcus aureus was observed by the same procedure as Example 1.
A hHRG solution was added to a neutrophil solution. The mixture was dispensed to a 96-well plate and incubated under CO2 at 37° C. for 30 min. Then, the Escherichia coli or Staphylococcus aureus pretreated with the above-mentioned HSA or HRG solution, or 5-fold-diluted human serum was added, and the resulting mixture was dispensed to the 96-well plate and incubated under CO2 at 37° C. for 120 min. The final concentration of the cell liquid at this time was 2×104 cells/well (2×105 cells/mL), the final concentration of HSA or HRG was 1.0 μM, and the final concentration of Zymosan was 25 μg/well (250 μg/mL). Through use of InCell Analyzer (GE Healthcare), the amounts of red-colored pHrodo by neutrophils' uptake were analyzed by image analysis and quantification to observe the phagocytosis ability of neutrophils.
In the results of this Experimental Example, the HRG pretreatment did not exhibit an opsonin (Op)-enhancing effect against Escherichia coli or Staphylococcus aureus. In contrast, the treatment with the 5-fold-diluted human serum exhibited a strong opsonin (Op) enhancement effect against Escherichia coli and Staphylococcus aureus. The HRG-pretreated bacterial cells did not enhance the phagocytosis ability of neutrophils, implying that HRG affects neutrophils rather than bacterial cells to enhance their phagocytosis ability. The phagocytosis ability of neutrophils of the bacterial cells opsonized (Op) with the human sera was highly enhanced by the addition of HRG as compared to un-opsonized (UnOp) bacterial cells, suggesting that phagocytosis actions of neutrophils against the opsonized (Op) bacterial cells in living bodies are further enhanced in the presence of HRG.
As described above in detail, the “agent for enhancing phagocytosis ability of neutrophils” of the present invention can enhance phagocytosis ability of neutrophils, and thus would be used as a therapeutic agent or therapeutic adjunct for various bacterial infectious diseases, viral infectious diseases, fungal infectious diseases, parasitic infectious diseases, and mixed infectious diseases thereof. The “agent for enhancing phagocytosis ability of neutrophils” of the present invention would be used with any other pharmaceutical formulation, for example, a therapeutic agent already put on the market or a therapeutic agent to be developed in the future, allowing the reduction in dose/administration frequency of the other pharmaceutical formulation. When the other pharmaceutical formulation has a side effect, the combined use of the other pharmaceutical formulation and the “agent for enhancing phagocytosis ability of neutrophils” of the present invention can reduce the dose/administration frequency of the other pharmaceutical formulation, which is useful.
| Number | Date | Country | Kind |
|---|---|---|---|
| 2018-123626 | Jun 2018 | JP | national |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/JP2019/022812 | 6/7/2019 | WO | 00 |
